Overzealous EU regulations "threaten MRI use and will impede research"
This article was originally published in Clinica
Use of and research on MRI in Europe is under serious threat because of what many deem to be overzealous regulations from Brussels that are now due to be implemented in member state law.
You may also be interested in...
Biopharma was an attractive investment in 2020 and fundamentals are unchanged in 2021, including the pandemic’s work-at-home requirements, which allowed more companies to go public faster.
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.